Foreign-Trade Zone (FTZ) 43-Battle Creek, Michigan, Notification of Proposed Production Activity, Pfizer, Inc., (Pharmaceutical Products), Kalamazoo, Michigan

---
identifier: "/us/fr/2017-11835"
source: "fr"
legal_status: "authoritative_unofficial"
title: "Foreign-Trade Zone (FTZ) 43-Battle Creek, Michigan, Notification of Proposed Production Activity, Pfizer, Inc., (Pharmaceutical Products), Kalamazoo, Michigan"
title_number: 0
title_name: "Federal Register"
section_number: "2017-11835"
section_name: "Foreign-Trade Zone (FTZ) 43-Battle Creek, Michigan, Notification of Proposed Production Activity, Pfizer, Inc., (Pharmaceutical Products), Kalamazoo, Michigan"
positive_law: false
currency: "2017-06-07"
last_updated: "2017-06-07"
format_version: "1.1.0"
generator: "[email protected]"
agency: "Commerce Department"
document_number: "2017-11835"
document_type: "notice"
publication_date: "2017-06-07"
agencies:
  - "Commerce Department"
  - "Foreign-Trade Zones Board"
fr_citation: "82 FR 26433"
fr_volume: 82
docket_ids:
  - "B-27-2017"
---


#  Foreign-Trade Zone (FTZ) 43—Battle Creek, Michigan, Notification of Proposed Production Activity, Pfizer, Inc., (Pharmaceutical Products),  Kalamazoo, Michigan

Pfizer Inc. (Pfizer) submitted a notification of proposed production activity to the FTZ Board for its facility in Kalamazoo, Michigan within Subzone 43E. The notification conforming to the requirements of the regulations of the FTZ Board (15 CFR 400.22) was received on April 12, 2017.

Pfizer already has authority to produce certain pharmaceutical products within Subzone 43E. The current request would add finished products and a foreign status material/component to the scope of authority. Pursuant to 15 CFR 400.14(b), additional FTZ authority would be limited to the specific foreign-status material/component and specific finished products described in the submitted notification (as described below) and subsequently authorized by the FTZ Board.

Production under FTZ procedures could exempt Pfizer from customs duty payments on the foreign-status material/components used in export production. On its domestic sales, Pfizer would be able to choose the duty rate during customs entry procedures that apply to crisaborole (Eucrisa <sub>TM</sub> ) (duty free) in finished product and bulk form for the  foreign-status material/component noted below and in the existing scope of authority. Customs duties also could possibly be deferred or reduced on foreign-status production equipment.

The material/component sourced from abroad is crisaborole—active pharmaceutical ingredient (duty rate 6.5%).

Public comment is invited from interested parties. Submissions shall be addressed to the Board's Executive Secretary at the address below. The closing period for their receipt is July 17, 2017.

A copy of the notification will be available for public inspection at the Office of the Executive Secretary, Foreign-Trade Zones Board, Room 21013, U.S. Department of Commerce, 1401 Constitution Avenue NW., Washington, DC 20230-0002, and in the “Reading Room” section of the Board's Web site, which is accessible via *www.trade.gov/ftz.*

For further information, contact Christopher Wedderburn at *[email protected]* or (202) 482-1963.

Dated: June 2, 2017.

Andrew McGilvray,

Executive Secretary.